Portfolio company
EnPlusOne
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops enzymatic RNA synthesis technology for biotechnology firms and pharmaceutical manufacturers to produce oligonucleotides for therapeutic applications.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Molecular Assemblies
This company develops enzymatic DNA synthesis technology to provide long, high-quality oligonucleotides for researchers in synthetic biology, therapeutics, diagnostics and data storage.
Ansa Biotechnologies
This company manufactures synthetic DNA using enzymatic synthesis technology for researchers in biological engineering, therapeutics, diagnostics and agriculture.
EnzyTag
This company develops and provides chemo-enzymatic peptide ligation technology and enzymes for pharmaceutical manufacturers to produce complex peptides and antibody-drug conjugates.
Nunabio
This company develops enzymatic technology for the synthesis of complex DNA sequences for customers in the biotechnology, pharmaceutical and materials science sectors.
Inceptive Nucleics
This company develops artificial intelligence models to design novel RNA-based medicines and biotechnologies for pharmaceutical and biotechnology partners.
Ansa Biotech
The company develops enzymatic DNA synthesis technology to provide complex genetic sequences for biopharmaceutical researchers and life science laboratories.
EnzyPep
EnzyPep develops enzymatic peptide synthesis technology and synthetic routes for pharmaceutical companies to produce polypeptides and bioconjugates.
DNA Script
This company develops benchtop enzymatic DNA synthesis instruments for life science researchers and laboratories to produce synthetic nucleic acids on demand.
